| アブストラクト | BACKGROUND: Daratumumab, a first-in-class humanized IgG1kappa monoclonal antibody that targets the CD38 epitope, has been approved for treatment of multiple myeloma by FDA. The current study was to evaluate daratumumab-related adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). RESEARCH DESIGN AND METHODS: Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN) and the multi-item gamma Poisson shrinker (MGPS) algorithms were employed to quantify the signals of daratumumab-associated AEs. RESULTS: Out of 10,378,816 reports collected from the FAERS database, 8727 reports of daratumumab-associated AEs were identified. A total of 183 significant disproportionality preferred terms (PTs) were retained. Unexpected significant AEs such as meningitis aseptic, leukoencephalopathy, tumor lysis syndrome, disseminated intravascular coagulation, hyperviscosity syndrome, sudden hearing loss, ileus and diverticular perforation were also detected. The median onset time of daratumumab-related AEs was 11 days (interquartile range [IQR] 0-76 days), and most of the cases occurred within 30 days. CONCLUSION: Our study found potential new and unexpected AEs signals for daratumumab, suggesting prospective clinical studies are needed to confirm these results and illustrate their relationship. |
|---|
| ジャーナル名 | Expert opinion on drug safety |
|---|
| Pubmed追加日 | 2024/4/11 |
|---|
| 投稿者 | Yun, Xiaolin; Zhou, Yingying; Wu, Danna; Liu, Yuanbo; Wu, Qiongshi |
|---|
| 組織名 | Department of Pharmacy, Hainan General Hospital, Hainan Affiliated Hospital of;Hainan Medical University, Haikou, Hainan, China.;Department of Pharmacy, Affiliated Hospital of Nantong University, Nantong,;Jiangsu, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38600747/ |
|---|
